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Abstract
Introduction Epidermal growth factor receptor (EGFR) is
involved in regulating cell growth in breast carcinomas. Its
activated form, phosphorylated EGFR (pEGFR), is correlated
with poor prognosis in lung cancer, but it has not yet been fully
investigated in breast cancer. The aim of this study was to
investigate the expressions of EGFR and pEGFR and their
correlation with overall and disease-free survival,
clinicopathological parameters and biological markers of
invasion and angiogenesis (phosphorylated Akt [pAkt],
urokinase plasminogen activator receptor [uPAR], matrix
metalloproteinase [MMP]-14, vascular endothelial growth factor
receptor [VEGFR]-1/Flt-1).
Methods A three-step immunohistochemical method was
applied to paraffin-embedded sections from 154 patients with
invasive breast carcinoma in order to detect expressions of the
proteins EGFR, pEGFR, oestrogen receptor, progesterone
receptor, c-erbB-2, pAkt, VEGFR-1/Flt-1, MMP-14 and uPAR.
The results were evaluated statistically using the χ2 test. Overall
and disease-free survival distribution curves were assessed
using the Kaplan-Meier test and log-rank statistics, followed by
Cox proportional hazards regression model.
Results EGFR and pEGFR proteins were immunodetected in
the membrane of the malignant cells (11.3% and 35.7%,
respectively). EGFR expression was positively correlated with
nuclear grade (P = 0.001) and negatively correlated with the
hormonal receptor oestrogen receptor (P = 0.005). pEGFR was
positively related to the Akt pathway (P = 0.008) and appeared
to participate in invasion and metastasis (uPAR, P = 0.049;
MMP-14, P = 0.025; VEGFR-1/Flt-1, P = 0.016). Univariate
analysis showed that the EGFR/pEGFR phenotype was
associated with poor overall survival (P  = 0.019), a finding
further supported by multivariate analysis (P = 0.013).
Conclusion These data provide evidence that pEGFR
expression is related to angiogenesis (via VEGFR-1/Flt-1, MMP-
14 and pAkt pathways) and invasiveness (via uPAR, MMP-14
and pAkt pathways) and that the EGFR/pEGFR phenotype is
associated with poor patient survival in invasive breast cancer.
Introduction
Epidermal growth factor receptor (EGFR) is a member of the
ErbB family, a family of tyrosine kinase receptors with growth-
promoting effects [1]. It is expressed in several carcinomas
[2,3] and high levels of expression are a common feature of the
malignant phenotype in many solid human tumours [4]. It is
activated by up to four different ligands, most commonly epi-
dermal growth factor (EGF) and transforming growth factor-
α(TGF-α), and forms homodimeric complexes or het-
erodimeric complexes with other members of the ErbB family
of receptors. Ligand binding and dimerization causes auto-
phosphorylation of the intracytoplasmic domains and activa-
tion of the intracellular tyrosine kinase. Activated EGFR
(phosphorylated EGFR [pEGFR]) stimulates a number of dif-
ferent signal transduction pathways, such as the Ras/mitogen-
activated protein kinase pathway, the phosphoinositide-3
kinase (PI3K)/Akt pathway and the phospholipase-Cγ/protein
kinase C pathway. The activation of these pathways initialize
with the recruitment of different adaptor proteins, which bind
to different phosphotyrosine residues of the cytopasmic tail of
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EGFR, and continues with a highly complex network of
enzymes, proteins and small-molecule secondary messengers
[5]. The signal transduction pathways activated by pEGFR
play important roles in various cellular processes, such as cell
proliferation, differentiation, adhesion, migration and apoptosis
[4,6].
EGFR is reported to be expressed in 14% to 91% of patients
with breast cancer [7-12], and in several studies it has also
been associated with poor prognosis [7], although its prog-
nostic value remains unclear. Recently, EGFR has once again
come to the fore, because of the development of several novel
drugs that target EGFR. Because EGFR has not proven to be
a useful prognostic/predictive marker of clinical response to
EGFR-targeted therapies [9,13], other prognostic/predictive
markers have been proposed, including the activated form of
EGFR (pEGFR) [14]. Previously, EGFR phosphorylation was
found to be associated with poor prognosis in non-small-cell
lung cancer patients and was suggested to be an important
predictor of clinical outcome [15,16].
The purpose of the present study was to gain further insight
into the prognostic significance of EGFR and pEGFR expres-
sion in invasive breast cancer. This was assessed in relation to
the classical clinicopathological parameters, clinical outcome
and the expression of biological markers of invasion and ang-
iogenesis (phosphorylated Akt [pAkt], urokinase plasminogen
activator receptor [uPAR], matrix metalloproteinase [MMP]-14
and vascular endothelial growth factor receptor [VEGFR]-1/
Flt-1).
Materials and methods
Patients and samples studied
A total of 154 paraffin blocks incorporating tumour samples
were available from patients with resectable breast cancer and
who had undergone surgery. We only selected women with
histologically proven, clearly invasive breast carcinomas,
regardless of their initial stage, in whom axillary lymph node
dissection had been performed and whose resected material
was studied histologically. The patients were aged 25 to 86
years (mean age 57.12 years). None of them had received
radiation or chemotherapy preoperatively. Finally, the material
acquired from them was used in research after they had pro-
vided informed consent, and we also obtained the institution's
approval before performing the study.
Routine histological examination was performed with haema-
toxylin-eosin staining. All carcinomas were classified accord-
ing to the criteria of the World Health Organization [17] and
were recorded as invasive ductal or invasive lobular. The com-
bined histological grade (1, 2 and 3) of infiltrating ductal car-
cinoma was obtained in accordance with a modified Scarff-
Bloom-Richardson histologic grading system, with guidelines
as suggested by Nottingham City Hospital pathologists [18].
Nuclear grading was based on nuclear polymorphism and
mitotic activity. Staging at the time of diagnosis was based on
the TNM (tumour-node-metastasis) system [19]. Tumour size
(<2 cm, 2 to 5 cm, >5 cm) and lymph node status were eval-
uated separately. The clinicopathological characteristics of the
series are shown in Table 1.
Follow up was available for 151 patients, of whom 39 died
from breast cancer and 54 had a recurrence. Mean survival
time was 94.83 months (range 5 to 135 months). Patient out-
come was defined as disease-free and overall survival rates.
Depending on the extent of their disease, all patients received
conventional postoperative treatment, including radiation ther-
apy and medical anti-oestrogen therapy, when indicated. Pre-
menopausal patients with axillary involvement were treated
with six courses of adjuvant chemotherapy.
Immunohistochemistry
Immunohistochemical staining for EGFR and pEGFR was per-
formed on 4 μm thick formalin-fixed paraffin sections, after
overnight heating at 37°C. Subsequent deparaffinization, rehy-
dration and antigen retrieval were performed in a one-step pro-
cedure with the EDTA (pH 8.0; Trilogy, Cell Marque, Rocklin,
CA, USA) in a microwave oven by heating the slides for 15
minutes. After rinsing with Tris-buffered saline, normal horse
serum was applied for 30 minutes to block nonspecific anti-
body binding. Subsequently, sections were incubated over-
night at 4°C with the primary antibody. A three-step technique
(Elite ABC Vector Laboratories, Burlingame, CA, USA) was
used for visualization, with diaminobenzidine as a chromogen.
Finally, sections were counterstained with haematoxylin and
mounted.
A mouse antihuman monoclonal antibody against EGFR
(clone 2-18C9, #1492; Dako, Glostrup, Denmark), ready for
use, and a rabbit monoclonal antibody against the pEGFR (Tyr
1173, #4407; Cell Signaling Technology, Beverly, MA, USA)
was used at a dilution of 1:100. According to the manufac-
turer, the anti-pEGFR antibody applied in the study does not
crossreact with other phosphorylated receptors of the HER
(human epidermal growth factor receptor) family. It detects
endogenous levels of EGFR only when it is phosphorylated at
tyrosine 1173; therefore, it is clear that this antibody targets
the pEGFR epitope.
The immunomarkers assessed in the present study, in combi-
nation with EGFR and pEGFR, had previously been detected
using the following antibodies: anti-oestrogen receptor (ER)
clone 1D5 (Dako) at a dilution of 1:450; anti-progesterone
receptor (PR) clone 1A6 (Dako) at a dilution of 1:150; anti-c-
erbB-2 clone BP53.12 (Oncogene, Cambridge, MA, USA) at
a dilution of 1:150; anti-pAkt (Thr308) rabbit monoclonal anti-
body (244F9, #4056; Cell Signaling Technology) at a dilution
of 1:40; anti-uPAR mouse antihuman domain 2 monoclonal
antibody (American Diagnostic Inc., Greenwich, CT, USA) at
a dilution of 1:100; anti-MMP-14 polyclonal antibody (Neo-Available online http://breast-cancer-research.com/content/10/3/R49
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Table 1
Correlation of EGFR and pEGFR expression with clinicopathological parameters, ER/PR, c-erbB-2, pAkt, uPAR, MMP-14 and 
VEGFR-1/Flt-1
Parameters Total EGFR PEGFR
n (%) Pn   (%) P
Menopausal status Premenopausal 50 5 (10.0) NS 13 (26.0) NS
Postmenopausal 104 13 (12.5) 42 (40.4)
Histological type Ductal 121 15 (12.4) NS 41 (33.9) NS
Lobular 32 3 (9.4) 13 (40.6)
Histological grade 1 23 1 (4.3) NS 7 (30.4) NS
2 90 11 (12.2) 35 (38.9)
3 36 6 (16.7) 11 (30.6)
Nuclear grade 1 53 1 (1.9) 0.001 18 (34.0) NS
2 53 5 (9.4) 23 (43.4)
3 47 12 (25.5) 13 (27.7)
Tumour size <2 cm 37 2 (5.4) NS 13 (35.1) NS
2 to 5 cm 91 11 (12.1) 32 (35.2)
>5 cm 25 5 (20.0) 9 (36.0)
Lymph node status Noninfiltrated 61 6 (9.8) NS 19 (31.1) NS
Infiltrated 91 12 (13.2) 35 (38.5)
Stage 1 28 2 (7.1) NS 9 (32.1) NS
2 97 12 (12.4) 33 (34.0)
3 27 4 (14.8) 12 (44.4)
ER Negative 70 14 (20.0) 0.005 20 (28.6) NS
Positive 83 4 (4.8) 35 (42.2)
PR Negative 78 13 (16.7) NS 30 (38.5) NS
Positive 75 5 (6.7) 25 (33.3)
c-erbB-2 Negative(<10) 60 5 (8.3) NS 21 (35.0) NS
Positive(≥ 10) 93 13 (14.0) 34 (36.6)
pAkt Negative (<10) 49 3 (6.1) NS 12 (24.5) 0.008
Positive (≥ 10) 72 11 (15.3) 35 (48.6)
uPAR Negative (<15) 49 9 (18.3) NS 12 (24.5) 0.049
Positive (≥ 15) 67 6 (9.0) 29 (43.3)
MMP-14 Negative (= 0) 93 13 (14.0) NS 28 (30.1) 0.025
Positive (>0) 29 2 (6.9) 16 (55.2)
VEFGR-1/Flt-1 Negative (<30) 40 5 (12.5) NS 9 (22.5) 0.016
Positive (≥ 30) 72 9 (12.5) 33 (45.8)
EGFR, epidermal growth factor receptor; ER, oestrogen receptor; MMP, matrix metalloproteinase; NS, not significant; pAkt, phosphorylated Akt; 
pEGFR, phosphorylated epidermal growth factor receptor; PR, progesterone receptor; uPAR, urokinase plasminogen activator receptor; VEGFR, 
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markers, Fremont, CA, USA) at a dilution of 1:120; and anti-
Flt-1 (VEGFR-1) rabbit polyclonal antibody (C-17) sc316
(Santa Cruz Biotechnology Inc., CA, USA) at a dilution of
1:80. The results with the aforementioned immunomarkers
were obtained from our archival database.
Evaluation of immunohistochemistry
The evaluation of the immunohistochemical staining was per-
formed by two pathologists, independently, through light
microscopic observation and without knowledge of the clinical
data from each patient. Cases of disagreement were reviewed
jointly to reach a consensus score. Evaluation was performed
by using the scoring system of Putti and coworkers [20] with
slight modifications. The extent of EGFR or pEGFR immunore-
activity was scored as 0 points for less than 5% positive cells,
1 point for 5% to 9% positive cells, 2 points for 10% to 50%
positive cells, and 3 points for more than 50% positive cells.
The intensity of EGFR or pEGFR immunoreactivity was scored
as 1 point for weak staining, 2 points for moderate staining,
and 3 points for strong staining. The overall score of the stain-
ing for each case was obtained by multiplying the extent of
immunoreactivity score with the intensity score. Cases with
overall score greater than or equal to 1 were considered pos-
itive. With regard to positive control, we used a breast cancer
tissue section previously known to over-express EGFR and
pEGFR (external control), along with a sample adjacent to can-
cerous tissues (internal staining control). Negative controls
had the primary antibody omitted and replaced by nonimmune
normal serum from the same species as the primary antibody
or Tris-buffered saline.
Staining for ER and PR was evaluated semiquantitatively using
the H score system, and a score greater than 50 was consid-
ered to be positive for both antigens [18]. The evaluation of the
immunostaining of anti-ER, anti-PR, anti-cerbB-2, anti-pAkt,
anti-uPAR, anti-MMP14 and anti-Flt-1 was performed, as
described previously [21-23]. The cut-off values of these
immunomarkers are shown in Table 1.
Statistical analysis
The significance of the relationship between the expression of
EGFR and pEGFR and clinicopathological parameters was
evaluated with univariate analysis using χ2 test and Fisher's
exact probability test. The effect of EGFR and pEGFR differ-
ential expression on postoperative survival rates was assessed
using both univariate (log-rank test) and multivariate (stepwise
forward Cox's proportional hazard regression model) analysis.
A  P  value under 0.05 was regarded to indicate statistical
significance.
Results
EGFR and pEGFR proteins were immunodetected in the
membrane of the malignant cells in 18 (11.3%) and 55 cases
(35.7%), respectively (Figure 1). Of 154 patients, eight (5.2%)
were both EGFR and pEGFR positive, 10 (6.5%) were EGFR
positive only, 47 (30.5%) were pEGFR positive only, and 89
(57.8%) were completely negative.
Based on expressions of EGFR, ER and c-erbB-2, only two
carcinomas were classified as breast carcinomas of basal-like
phenotype (EGFR-positive, ER-negative and c-erbB-2 nega-
tive). None of the studied proteins was associated with meno-
pausal status, tumour size, lymph node status, tumour stage,
PR hormonal status and c-erbB-2 protein.
EGFR immunoexpression was related to nuclear grade (P =
0.001) and inversely related to ER receptor status (P  =
0.005). Immunoexpression of pEGFR was associated with
pAkt, uPAR, MMP-14 and VEGFR-1/Flt-1 (P = 0.008, P =
0.049, P = 0.025 and P = 0.016, respectively). Coexpression
of EGFR/pEGFR was statistically associated with pAkt, MMP-
14 and VEGFR-1/Flt-1 (P = 0.011, P = 0.039 and P = 0.019,
respectively).
With regard to their prognostic significance, EGFR and
pEGFR were found to have an unfavourable associated with
overall survival (P = 0.046 and P = 0.032, respectively), but
Figure 1
Immunohistochemisty of EGFR and pEGFR in invasive breast carcinoma Immunohistochemisty of EGFR and pEGFR in invasive breast carcinoma. Intense membrane staining of (a) EGFR (ABC/HRPX200) and of (b) 
pEGFR (ABC/HRPX400) in two cases of invasive ductal breast carcinoma. EGFR, epidermal growth factor receptor; pEGFR, phosphorylated epi-
dermal growth factor receptor.Available online http://breast-cancer-research.com/content/10/3/R49
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not with disease-free survival (univariate analysis). Interest-
ingly, patients with synchronous expression of EGFR and
pEGFR had worse prognosis (P = 0.019) than did EGFR-pos-
itive or pEGFR-positive patients and totally negative patients
(Figure 2). Moreover, in multivariate analysis adjusted for
numerous factors (age, menopausal status, histological type,
histological grade, tumour size, lymph node status, ER, PR, c-
erbB-2, EGFR, pEGFR and EGFR/pEGFR phenotype),
tumour size (P = 0.010; B coefficient = 6.550; standard error
= 0.728, 95% confidence interval = 1.573 to 27.281) and
EGFR/pEGFR coexpression (P  = 0.013; B coefficient =
1.520; standard error = 0.168, 95% confidence interval =
1.093 to 2.113) were of independent prognostic significance
for overall survival.
Discussion
This study examined the expression of EGFR and its activated
form, pEGFR, in invasive breast carcinoma. We demonstrated
that EGFR and pEGFR are both expressed in the membrane
of 11.3% and 35.7% of tumour cells. The greater rate of pos-
itivity for pEGFR than for EGFR could be attributed to the
EGFR downregulation process. Once EGFR is activated it
undergoes internalization, resulting in a marked decrease in
nonactivated membrane-bound EGFR [24]. In previous stud-
ies, EGFR immunopositivity exhibits great variety [7-12]. The
wide range of EGFR expression (14% to 91%) may be
accounted for by use of different methods and different criteria
for assessment, as well by the presence of basal-like carcino-
mas that consistently over-express EGFR.
None of the studied proteins was associated with menopausal
status, tumor size, lymph node status, tumour stage and PR
hormonal status, which is in accordance with the majority of
reports on EGFR expression [9,25]. The absence of any asso-
ciation between EGFR and c-erbB-2 expression may be due
to variations in c-erbB-4 expression, which antagonizes the
influence of c-erbB-2 in tumors [7].
With regard to EGFR, we showed that its expression was pos-
itively associated with nuclear grade (P = 0.001) and inversely
associated with ER hormonal status (P = 0.005), which is in
accordance with a large number of studies [25,26]. This con-
sistent finding in much of the literature had led to the plausible
hypothesis that EGFR signalling may be associated with endo-
crine resistance or insensitivity [27-29]. Alternatively, this find-
ing may be accounted for by the strong association between
EGFR expression and loss of differentiation in breast cancer.
EGFR activation has an antiapoptotic effect through PI3K
pathway [1], a fact that was corroborated by the pEGFR rela-
tionship to pAkt (P = 0.014). EGFR can lead to activation of
PI3K both directly and indirectly through Ras; it induces down-
stream activation of phosphoinositide-dependent protein
kinase-1 and -2 that phosphorylate thr308 and ser473 on Akt,
respectively. Akt's antiapoptotic role is well known, via phos-
Figure 2
Univariate analysis (log-rank test) of overall survival Univariate analysis (log-rank test) of overall survival. Schematic repre-
sentation of the impact of (a) EGFR, (b) pEGFR and (c) EGFR/pEGFR 
expression on overall survival (OS). EGFR, epidermal growth factor 
receptor; pEGFR, phosphorylated epidermal growth factor receptor.Breast Cancer Research    Vol 10 No 3    Magkou et al.
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phorylating and sequestering downstream targets including
the FOXO family of forkhead transcription factors, the proap-
optotic Bad and the protease caspase-9, and by activating the
pro-survival transcriptional regulator protein nuclear factor-κB.
Expression of pEGFR was associated with VEGFR-1/Flt-1
and MMP-14. VEGFR-1/Flt-1 is a specific endothelial cell
receptor to which the angiogenic factors VEGF-A and VEGF-
B bind; it promotes differentiation and vascular maintenance
[30]. Indeed, in tumour progression EGFR upregulates
VEGFR; thus, it is implicated in angiogenesis. In addition, in
human cancer cells the EGFR autocrine pathway controls the
production of several proangiogenic growth factors, including
VEGF [4]. It is also known that several EGFR inhibitors, such
as monoclonal antibodies, result in a concurrent downregula-
tion of tumour-induced, VEGF-mediated angiogenesis [4].
Therefore, the above-mentioned relationship implies an angio-
genetic role of activated EGFR. The angiogenetic ability of
pEGFR has further confirmed by the pEGFR association with
pAkt, which is known to modulate angiogenesis via activation
of endothelial nitric oxide synthase [31]. MMP-14, as well as
most of the MMPs, may promote angiogenesis by at least two
different mechanisms: by degrading barriers and allowing
endothelial cell invasion; or by liberating factors that promote
or maintain the angiogenic phenotype [32]. In addition, it pro-
motes invasion and metastasis by degrading ectracellular
matrix [33]. It appears that the above-mentioned relationship
between EGFR and MMP-14 reflects the well established
interaction between EGFR pathway and the MMPs [1]. EGFR
activation is able to upregulate MMPs, whereas MMPs partic-
ipate in several pathways of EGFR activation, such as the
ectodomain shedding of EGFR transmembrane precursor [4],
G protein-coupled receptor-mediated transactivation, and
uPAR-mediated transactivation of EGFR [1].
The combination of EGFR/pEGFR was associated with pAkt,
MMP-14 and VEGFR-1, which may be accounted for by the
parallel relationship between pEGFR and those biological
parameters.
Another observation in the present study, that of the parallel
relationship between pEGFR and uPAR, supports the exist-
ence of a uPAR-mediated EGFR transactivation pathway [1]
and enforces the invasive effect of pEGFR. The uPAR glyco-
protein, receptor of plasminogen activation system, plays a
central role in extracellular matrix degradation; thus, it partici-
pates in tumour invasion and metastasis [34]. Previously, in
breast cancer, it has been related to tumour aggressiveness
and patients poor survival [21].
With regard to the association of EGFR and pEGFR with
prognosis and survival, we found that EGFR and its active form
are significantly associated with overall survival (P = 0.035
and P = 0.016, respectively) but not with disease-free survival
in univariate analysis. Findings from previous studies regarding
prognostic significance of EGFR are controversial. Tsuitsu
and coworkers [11] reported the prognostic value of EGFR for
overall and disease-free survival, whereas other investigators
failed to confirm its prognostic significance in either the
entirety of studied cases [7-9] or in lymph node positive [8] or
-negative cases [35,36]. On the other hand, there is no report
about pEGFR expression and prognosis in breast cancer, as
far as we know, whereas in our study pEGFR appeared to
have an unfavourable impact on overall survival. We also
observed that EGFR-positive/pEGFR-positive tumours had
worse prognosis in contrast to EGFR-negative and/or pEGFR-
negative ones. Moreover, EGFR/pEGFR was found to be an
independent prognostic indicator for overall survival. EGFR
and pEGFR coexpression appears to be more representative
of EGFR dynamics in tumour than solely EGFR or pEGFR
expression. Probably, in EGFR-positive/pEGFR-positive
tumours, the total number of receptors is greater; thus, there
are more receptors available for subsequent phosphorylation.
Another possible explanation might be the existence of an
inhibitory mechanism, which impedes autophosphorylation of
several receptors and permits only a few receptors to become
phosphorylated and initiate EGFR-dependent signalling
cascades.
Nieto and coworkers [37] also studied EGFR and pEGFR
expression in invasive breast cancer, but they failed to attribute
any prognostic value to pEGFR expression. To the best of our
knowledge, there are no published data confirming the prog-
nostic value of pEGFR or EGFR/pEGFR coexpression in
breast cancer. Interestingly, Arteaga and Baselga [14] have
noticed that EGFR-positive colon carcinomas with simultane-
ous expression of pEGFR, coexpressed the EGFR ligand
transforming growth factor-α and markers of tumour prolifera-
tion, which is in contrast to EGFR-positive/pEGFR-negative
carcinomas. Thus, EGFR content in EGFR-positive/pEGFR-
negative tumours does not reflect the level of receptor
activation.
Conclusion
In the present study, simultaneous expression of both forms of
EGFR emerged as a more promising prognostic marker in
invasive breast carcinomas. However, more research is
needed to clarify the importance of EGFR/pEGFR immunoex-
pression to prognosis, as well as the applicability of pEGFR
expression and amplification in targeted therapies.
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